ZIOP - Earnings call transcript Q3 2021 | Alaunos Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to ZIOPHARM Oncology Third Quarter 2021 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require Operator assistance during the conference, please press star 0 on your telephone keypad. is conference this note being recorded. Please now Alex Lobo, will turn the host, your to over Chair conference I Investor Relations. Thank you.

You may begin.

Alex Lobo

results announcing afternoon a well the results September Form Vice Research this audio also at Baffa ZIOPHARM's, be XXXX. Good of President ZIOPHARM's, Chief quarterly and for are with quarter months three XXth, ZIOPHARM's of you. and filed Medical press SEC. ziopharm.com. and on today's available Oncology's on Senior, ZIOPHARM financial ZIOPHARM been afternoon, third the Thank Raffaele Officer, third We ended Kevin release XXXX Boyle read financial Earlier quarterly to With The Officer, of reports conference press encourage has and press website XXXX XX-Q webcast. and Chief report as will release everyone Development. Executive call for issued me today welcome the release, which quarter and Executive as ZIOPHARM's company's

November In the call is or will call Private through call set business. filings under Harbor and the those and any XXXX. this accurate the reflect most risks for to to from risks section time-sensitive broadcast, with be are on information update SEC webcast forth that addition, over as of that to information this Actual Relations the Reform securities future obligation or only of statements date materially of of are that would sec.gov. results now discussed revise events said, with by at differ the I like stated company as webcast, by the in cautioned company's potential Securities and on the Xth, Litigation date public conference The required may there undertakes archived covered certain our to XXXX. company's these live forward-looking be recent Participants this are Act could Kevin, uncertainties Boyle. provisions that today's after call Information With conference contains or implied associated you of Please the of note may this the website turn is statements begin. Investor reference. Safe circumstances no due uncertainties to applicable Kevin forward-looking except being law.

Kevin Boyle

our the differentiated you our out our like Alex. made that Thank highlight joined to and everyone the recent I 's and two of TCR-T next earnings ZIOPHARM months lay and decision strategically to When platform. month observations my cell for accomplishments organization my ZIOPHARM the And ago, shareholders just A over welcome to promise quarter do and third perspectives to I some transparent on efforts at Today, I'd focus we call. and vision with year. share opportunity. restructure be next the ago, XXXX advancing

in to begin ZIOPHARM of treating excellent The remain did team October first or to at proud operationalize an disciplinary on innovative We and As important I'm a and production our maintaining working focus unit with external quality, half in-house a team CPU. the on the step. dedication, generating by the very engine. an result, discovery in I'm impressed our our CPU. announce the together while that took completed we we the necessary scientific our CGMP excellent job engineering was into that clinical to immediate contract but to regard. XXXX. in fastest clinical to appreciate validate progress accomplish manufacturer, importance rely in generating platform, possess I'm the research TCR-T of advance making confident to We are clinic. internal the data robust organization R&D action a resiliency our we and the across ZIOPHARM, patients manner right-size at runs to and way qualification this not realized committed the clinic process to clinical of capabilities We to data

on research is lab programs. TCR-T working a team and robust is predicated several and platform The based development on different Our R&D in team Houston.

we program, IND. are trial, support the lead TCR-T to into TCRs incorporate our additional and to library continue First, this working

Second, the updates development membrane future XX bound we are calls. advancing to program expect have of and aisle further our on

let am we use These own the our have impressed into cancer devoted -T team resources allow R&D I of take briefly and TCR of depth upcoming holds improve of to for breadth dive significant identified. I Third, want our a library which will our Raffaele deeper platform. the rationale program. and platform, will to but elaborate TCR-T own discovery TCRs potential have on property exclusive patients. generate our to the the TCR this lives and generating our intellectual to meaningfully we activities us study, I by

cost-effective our to clinical, Officer, multiple library TCR-T our Sleeping library we and manufacturing, in we versatile this over a Raffaele, an solid are will extensive generated efforts this our with to and now to indications and This enabled platform Chief of that stakeholders. us like This the This Our technology combined platform our benefit multiple growth approach this an us several forward within turn and study. is critical our to single by target timely support paths strategy, set. provide initial that to go-forward advantage identifying Medical as trial. we once Raffaele. bring focused on data our is update indications tumor give future non-viral Beauty our gives first to could can I dosing call TCRs. have across our patient enables R&D TCR-T our from would value potentially and

Raffaele Baffa

to are Kevin. data Thank all year. and programs, said, manufacturing, quarter, activities. in like progress And ZIOPHARM clinical continued in next Kevin to This across development R&D make us the we have all of at past execution you generating our committed

me [inaudible XX:XX:XX] progress that have manufacturing Let by Houston, we facility Texas. highlighting the start made in

second recently validation completed facility, the the well quarter CPU. process built of have process own?CGMP? clinical qualification as the opening we We and the CPU. in as Commissioning safety and our and in engineering of completed ramp are unit production were

patient We we patients are library capability TCR-T of X/X our committed in a expect in the XXXX. first in support Phase dosing operationalized, dosing third the similar the to begin half to study first of Once to having manufacturing XXXX. half operational

neoantigen. them Cancer library duct screening will a are As TCR -T that that basket autologous pancreatic, Kevin T and being library. study will TCR month, actively the trial matching using ovarian Sales enrolled across Last Sleeping lung, express our study screening endometrial, our MD is engineered on indications; bile patients the colorectal the cells, fuse mentioned, on based evaluate actually service against that in Beauty open Patients are being study to trial levels. XX:XX:XX] be reactive it identify with that we with Technology. X-X tumor gives -antigen we are Phase and available neo library patients patients then and Research bearing optimal X-solid X at Transco And We our portion that Anderson treatment sectors The rapidly Center, itself on our cancers. TCR-T and as our clinical to is us design recommended approach patient's translate [inaudible believe will meaningful or effectively, and study that much indications. such the trial, Phase profile us to therapies seek of evaluate of X engine adaptive tumor as our multiple develop genetic first will the cost forward, advancing to finding progress. TCR-T the Phase dose dose, allow an dose agnostic we on to one more one and cancer This Development in move the registrational quickly of into X opportunity to across the our

pre an As of you may year, ACR recall, multiple specificity data our in on at frequent shared demonstrated with to On of targeting, recurrence, our unique with the of [inaudible these Immunotherapy program. TCR-T at strong will update Society HLA exciting annual These substitution [inaudible the data TCRs this science the Xth a earlier beyond TCRs. -clinical we will Meeting, we CT, provide XXXX Saturday, Cancer, conference on XX:XX:XX]. further Annual XX:XX:XX]

TCR bio On platform utility up we upcoming for turn the we this and file and Furthermore, validate to population owned tributary the and include that in Finally, further innovative TCR-T resources, IND over TCRs to like are to are financial internal targets including Kevin? back developed cellular subject, to generate results months validate patient for exclusivity applicable to TCR-T informatics, into to continuing Kevin, an now immunology, library the our plan genomics, expand next qualify round trials. to call strategy, have go-forward few would to library. by with TCR to the the our I us. new we review and an potential quarter. our

Kevin Boyle

Raffaele. you Thank

XXXX, expenses expenses increase development million and Research XXXX. of same to quarter a third million of to third for $XX.X net or for a loss the approximately of quarter or $X.XX third approximately loss For the of million $XX net $XX.X loss for XXXX, approximately approximately reported the cash increase $X.XX share for per quarter a million $XX.X XX%. million share approximately net compared per in an net compared of for and third and for XXXX period loss million. Total X%. approximately were equivalents, quarter expenses million General of Cash million the third as September same were million in the XXXX, period the to $XX.X of third XXXX XXXX, of $X.X to quarter XX, of an compared $X.X quarter for approximately administrative compared approximately $XX.X of XXXX. $XX.X XXXX, an approximately totaled the the we're we operating

close cost continued efforts, we before TCR-T to into and questions, our financial of building Given concludes the But call the statements. our development anticipate like are our to to runway extend management quarter that will open a committed That current leading XXXX. we plans cash company. second I'd saying by we

success. We appropriately for have capitalized is organization an staffed created and that

remain we Over into have focused research the next year, developed scientific the will transforming clinical on innovative progress. we

our operationalizing the facility, enter we cash TCR-T clinical generate to data XXXX. are on quarter progress our in-house operations fund in library clinic manufacturing second program with excellent existing to sufficient confident our meaningful ability into made have in with and We of the our and XXXX,

focused clear as and these team is entire cancer achievable to in lives we at priorities stakeholders bring and With value here our ZIOPHARM place, to of patients. the aim execution strategic on improve our

call now will questions. to Hilary. the open We

Operator

this be conducting while Thank we moment, session. please, One for you. poll a [Operator we will question-and-answer At time, questions. Instructions].

is your Fitzgerald. Please of question. with Our proceed first question Alethia from Young Cantor

Emily Milligan

plus And made Emily maybe how manufacturing. the to X and taking expenses X maybe now are your on Hi, well? I'm you've for the curious the you. Thanks Alethis. phase starting comment the Thank on quarter fourth with for expect that questions. in what do operating gating the change as also the study you then, this factors you've that done just progress restructuring, XXXX in-house just in now to our is

Kevin Boyle

with forward second our $XX that less Great. anticipate the we a burn, Thanks, quarter. going cash regards than one burn to be Emily. start I'll first. With will million

reporting on forward as cash be will that's we so, our burn And something that well. going

And in we with some of loan associated future the cash was repaying term look is well in as that the as horizon. put place the

of spelled remaining terms have the cash reduction team do are on XX-Q. those goals. band our size appropriate we so, into out But in loan And our execute while a to our term nice the

treating regards it's in the Now, all-clear patients IND trial, FDA. to from with our the we that our on important have

So patients. the enrolling and review you'd part FDA step add the screening to to important most the probably that? like is Raffaele, next anything to along with

Raffaele Baffa

Just said screening we actively that patients. screening already as started patients, I earlier,

are the Phase our will starts. when that We patients, treatment already role screening be X/X

Emily Milligan

you. Thank Okay

Kevin Boyle

Thanks Emily.

Operator

Arthur Hey, with question. Please is Wainwright. question H.C. your from proceed next Our of

Arthur Hey

Hey afternoon for Arthur is for thanks XX:XX:XX], Good [inaudible This my taking everyone. question.

Could to follow-up that else you guys see trial? qualified first patient want in I the be to on the dose So trial. complete give be us or to just to what studying more you TCR-T before to I need colors guess

Kevin Boyle

to you Raffaele, to Emily? before do reiterate we want said what

Raffaele Baffa

Exactly.

review for already And Kevin FDA waiting be on are a that trial. as patients mentioned are screening We roll the we the can earlier.

duly have the soon, would we're patients half but mind to frequency But we're and I that the of ready keep of you mutations start to enrolling selecting in in XXXX. these say, Now, (ph). and fairly that patients first Apple-type the

Arthur Hey

more that. commercial what's part. for part, the the your on want you I manufacturing, or know And that clinical the manufacturing Thank trial, most for on about you. for manufacturing those likely how just plan it's for part? to Thank you. Thank congratulations Okay.

Kevin Boyle

you. Thank Yes.

will quite that's For of the now, part, what our manufacturing have strategy years clinical be that we commercial side, at away we not from communicated point. capabilities, number our and on have a right the

Arthur Hey

Okay.

for my great. Thank you taking you. Thank question. Sounds

Kevin Boyle

Thank you, Arthur.

Operator

is Our Flaten Capital Please your of proceed Street question. Lake Thomas next from question Markets. with

Thomas Flaten

just been the taking departures? for staff you there to any following Thanks guys. had curious there afternoon, that restructuring curious strategies unforeseen has what Good other put staff. just the left any I that been Have was that's had. in Have question. retention keep remaining I'm the behind? impact place the on the

Kevin Boyle

time, regards grant We all stock value Thanks, aligned incentive are shareholders, in and for same that sure and incentivizing creating we option put our with did team. at motivating to make Thoms. to the our

And any resignations by everybody and been so, surprise. that been had hard, have well-received as team, very has not a the And aligned. much working that has very we come

So team team, amount next effort up well-positioned is of patients are we're the just who with enrolling team, we very And and coming as this and And to the we of reiterate retention our quite running half the that team strategic of year. core strength keeping. we're with The of resiliency very I excited that this the and first team. really get impressive, clinical of ended here the up deliverables and out have. and the a of trial in

Thomas Flaten

if but to new prior that. go the respect as rolling you will to And IND clearance, apologize or you TCRs? ongoing this, with missed exercise TCRs to identify the IND that that new for be anticipating through an are I adding Thanks clearance I you

Kevin Boyle

Raffaele, why to speak don't that. you

Raffaele Baffa

Yes.

wouldn't the TCR X are the adding planning So TCR or in year. line I mentioned come not additional a but for the with put XX:XX:XX] in [inaudible that submission time manner, earlier, time only next we connection a but that will I

Thomas Flaten

finally then, -- And Great.

Raffaele Baffa

though. I together, wouldn't the link thing

Thomas Flaten

And how just final things NCI word Got then out there? going on over it. of understood. question. are No, Any one the

Kevin Boyle

have part any this will the now but believe the to to Visit, NCI. don't team regards I the visiting week right that So we as with NCI and update Raffaele SITSI be later share of

Thomas Flaten

the appreciate so question. I taking Thanks Great. much.

Kevin Boyle

Thank you.

Operator

time. reached may session. and your today's great you the question-and-answer of this Thank and day. participation, have disconnect We conference, for end have the This concludes lines a you your at

Alaunos Therapeutics (TCRT) 9 Nov 212021 Q3 Earnings call transcript